Oncolytic Virus Therapy: Harnessing Engineered Viruses to Revolutionize Precision Cancer Treatment

 

Introduction

Cancer remains one of the leading causes of mortality worldwide despite decades of groundbreaking research and remarkable advances in diagnosis, surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. According to global cancer statistics, millions of new cancer cases are diagnosed each year, creating an urgent need for innovative treatment strategies that are more effective, personalized, and capable of overcoming drug resistance. While conventional therapies have significantly improved patient survival, many aggressive cancers continue to evade treatment through complex biological mechanisms, highlighting the importance of developing next-generation therapeutic approaches.

One of the most exciting breakthroughs in modern oncology is Oncolytic Virus Therapy (OVT)—an innovative form of cancer immunotherapy that utilizes genetically engineered or naturally occurring viruses to selectively infect, replicate within, and destroy cancer cells while leaving healthy tissues largely unharmed. Unlike traditional antiviral strategies that eliminate viruses, oncolytic virotherapy harnesses the natural ability of viruses to invade cells and redirects this power against malignant tumors.

Beyond directly killing cancer cells, oncolytic viruses activate the body's immune system by releasing tumor-associated antigens, transforming immunologically "cold" tumors into "hot" tumors that become more responsive to immune checkpoint inhibitors and other immunotherapies. This dual mechanism—combining direct tumor destruction with immune activation—positions oncolytic virus therapy as one of the most promising frontiers in precision oncology.

Recent years have witnessed remarkable progress in this field, including the approval of Talimogene Laherparepvec (T-VEC), the world's first FDA-approved oncolytic virus therapy for advanced melanoma. Numerous clinical trials are currently evaluating engineered adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, and other viral platforms across a broad spectrum of solid tumors and hematologic malignancies.

As researchers continue to integrate artificial intelligence, genomic profiling, precision medicine, biomarker discovery, and personalized immunotherapy, oncolytic viruses are becoming an integral component of next-generation cancer treatment strategies.

In this comprehensive article, we explore the science behind oncolytic virus therapy, its mechanisms of action, clinical applications, recent advances, ongoing challenges, and the future of engineered viral therapies in transforming precision cancer care.

Understanding Oncolytic Virus Therapy: What It Is and How It Works

Oncolytic Virus Therapy (OVT) is an innovative and rapidly evolving form of cancer immunotherapy that employs naturally occurring or genetically engineered viruses to selectively infect, replicate within, and destroy cancer cells while minimizing damage to healthy tissues. Unlike conventional antiviral medicine, which focuses on eliminating viruses, oncolytic virotherapy transforms viruses into powerful therapeutic agents capable of targeting malignant tumors with remarkable specificity.

The concept of using viruses to treat cancer dates back more than a century, when physicians observed that some cancer patients experienced temporary tumor regression following natural viral infections. These early observations inspired researchers to investigate how viruses could be modified to safely attack cancer cells. Advances in molecular biology, virology, genetic engineering, and precision medicine have now made it possible to develop highly targeted oncolytic viruses with enhanced safety profiles and improved therapeutic effectiveness.

Modern oncolytic viruses are specifically designed to recognize and exploit the unique biological characteristics of cancer cells. Tumor cells often possess defective antiviral defense mechanisms, abnormal signaling pathways, rapid cell division, and altered immune responses. These abnormalities create an ideal environment for viral replication. Healthy cells, in contrast, retain intact antiviral mechanisms that prevent viral multiplication, thereby protecting normal tissues from significant damage.

 

The Two-Step Mechanism of Oncolytic Virus Therapy

One of the most remarkable features of oncolytic virus therapy is its dual mechanism of action, which combines direct destruction of tumor cells with activation of the patient's immune system.

1. Selective Infection and Viral Replication

The therapeutic virus enters the patient's body through intratumoral injection or intravenous administration, depending on the type of cancer and viral platform. Once inside the body, the virus preferentially identifies and infects cancer cells because of their abnormal surface receptors and impaired antiviral signaling pathways.

After entering a tumor cell, the virus hijacks the cellular machinery to produce thousands of new viral particles. As viral replication continues, the infected cancer cell becomes overwhelmed and eventually ruptures in a process known as oncolysis. This destruction releases newly formed viruses, which spread to neighboring cancer cells and repeat the cycle, amplifying the therapeutic effect throughout the tumor.

 

2. Activation of Anti-Tumor Immunity

The benefits of oncolytic virus therapy extend far beyond direct tumor destruction.

When infected cancer cells rupture, they release:

• Tumor-associated antigens (TAAs)
• Tumor-specific neoantigens
• Viral proteins
• Damage-associated molecular patterns (DAMPs)
• Cytokines and inflammatory mediators

These molecules serve as danger signals that alert the immune system. Dendritic cells capture these tumor antigens and present them to T lymphocytes, initiating a robust adaptive immune response against remaining cancer cells throughout the body.

As a result, oncolytic viruses transform immunologically "cold" tumors—those with little immune activity—into "hot" tumors that become more recognizable and vulnerable to immune attack.

This immune activation also explains why oncolytic virus therapy is increasingly being combined with immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 therapies to achieve stronger and more durable clinical responses.

 

Why Do Oncolytic Viruses Target Cancer Cells?

Cancer cells differ significantly from healthy cells in several biological aspects that make them highly susceptible to viral infection.

These differences include:

• Defective interferon signaling pathways
• Rapid and uncontrolled cellular proliferation
• Increased metabolic activity
• Abnormal cell surface receptors
• Genomic instability
• Impaired antiviral immune responses
• Altered tumor microenvironment

Because of these abnormalities, engineered viruses replicate efficiently inside malignant cells while healthy tissues can usually suppress viral replication before significant damage occurs.

This selective targeting represents one of the greatest advantages of oncolytic virotherapy over conventional chemotherapy, which often affects both cancerous and healthy rapidly dividing cells.

 

Types of Oncolytic Viruses Under Investigation

Several viral platforms are currently being explored in preclinical and clinical research for cancer therapy.

Herpes Simplex Virus (HSV-1)

HSV-based oncolytic viruses are among the most extensively studied. The genetically modified HSV-1 therapy Talimogene Laherparepvec (T-VEC) became the first FDA-approved oncolytic virus for treating advanced melanoma. It is engineered to selectively replicate within tumors while producing granulocyte-macrophage colony-stimulating factor (GM-CSF), which further enhances anti-tumor immunity.

 

Adenovirus

Adenoviruses are highly versatile vectors that can be genetically modified to selectively replicate in cancer cells. They are being investigated for various solid tumors, including prostate, pancreatic, lung, colorectal, and head-and-neck cancers.

 

Vaccinia Virus

Originally developed for smallpox vaccination, vaccinia viruses possess a large genetic capacity, allowing researchers to insert multiple therapeutic genes. Their rapid replication and strong immune stimulation make them attractive candidates for combination immunotherapy.

 

Reovirus

Reoviruses naturally replicate in tumors with activated RAS signaling pathways. Since RAS mutations are common in pancreatic, colorectal, and lung cancers, reovirus-based therapies are under active investigation for these malignancies.

 

Measles Virus

Engineered measles viruses have shown encouraging activity against multiple myeloma, ovarian cancer, and glioblastoma by selectively infecting cancer cells expressing high levels of CD46 receptors.

 

New Emerging Viral Platforms

Researchers are also developing:

• Coxsackievirus
• Newcastle Disease Virus (NDV)
• Vesicular Stomatitis Virus (VSV)
• Poliovirus-based therapies
• Seneca Valley Virus
• Parvoviruses

Each viral platform offers unique biological characteristics that may be suited for different tumor types and therapeutic strategies.

 

Why Oncolytic Virus Therapy Represents Precision Oncology

Oncolytic virus therapy exemplifies the principles of precision oncology because treatment can be tailored according to:

• Tumor genetics
• Biomarker expression
• Immune landscape
• Viral susceptibility
• Molecular profiling
• Personalized immunotherapy combinations

Future treatment strategies are expected to integrate genomic sequencing, artificial intelligence, biomarker discovery, and multi-omics analysis to identify the most suitable viral platform for each individual patient.

As precision medicine continues to evolve, oncolytic viruses are likely to become an essential component of personalized cancer care, offering highly targeted treatments with improved efficacy and reduced toxicity compared with many conventional therapies.

Clinical Applications of Oncolytic Virus Therapy Across Different Cancer Types

The remarkable versatility of oncolytic virus therapy has led to its investigation across a wide range of solid tumors and hematologic malignancies. Advances in genetic engineering, precision oncology, and immunotherapy have enabled researchers to design tumor-selective viruses capable of targeting specific cancer types while simultaneously activating systemic anti-tumor immunity.

Today, hundreds of clinical trials worldwide are evaluating oncolytic viruses as standalone treatments and in combination with chemotherapy, radiotherapy, immune checkpoint inhibitors, CAR-T cell therapy, and targeted therapies. Although only one oncolytic virus therapy has received regulatory approval so far, the expanding clinical pipeline demonstrates enormous potential for future cancer care.

 

1. Advanced Melanoma

Melanoma remains the most successful clinical application of oncolytic virus therapy.

The U.S. Food and Drug Administration (FDA) approved Talimogene Laherparepvec (T-VEC), a genetically modified herpes simplex virus type 1 (HSV-1), for the treatment of unresectable melanoma lesions. T-VEC selectively infects melanoma cells, causing direct tumor destruction while expressing Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to stimulate a powerful anti-tumor immune response.

Clinical studies have demonstrated:

• Significant reduction in injectable melanoma lesions
• Durable response rates in selected patients
• Improved immune activation
• Better outcomes when combined with immune checkpoint inhibitors

Melanoma continues to serve as a model disease for evaluating next-generation oncolytic viruses.

 

2. Glioblastoma (Brain Cancer)

Glioblastoma is one of the most aggressive and treatment-resistant brain tumors. Despite surgery, radiotherapy, and chemotherapy, long-term survival remains poor.

Researchers are investigating several engineered viruses, including:

• Herpes Simplex Virus (HSV)
• Adenovirus
• Poliovirus
• Newcastle Disease Virus

These viruses are designed to penetrate tumor tissue, selectively infect glioblastoma cells, and stimulate local immune responses within the brain.

Early clinical trials have shown encouraging results in improving survival for selected patients while maintaining acceptable safety profiles.

 

3. Pancreatic Cancer

Pancreatic cancer is often diagnosed at advanced stages and is characterized by a highly immunosuppressive tumor microenvironment.

Oncolytic viruses offer several advantages:

• Direct destruction of pancreatic tumor cells
• Increased immune cell infiltration
• Improved sensitivity to chemotherapy
• Enhanced response to immune checkpoint inhibitors

Several adenovirus-based and reovirus-based therapies are currently undergoing clinical evaluation for pancreatic adenocarcinoma.

 

4. Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers.

Current research is exploring combinations of oncolytic viruses with:

• Anti-PD-1 therapy
• Anti-PD-L1 therapy
• Chemotherapy
• Radiotherapy

These combination approaches aim to convert immune-resistant tumors into immunologically active tumors, improving patient response rates and long-term survival.

 

5. Colorectal Cancer

Colorectal cancer frequently develops resistance to conventional chemotherapy and targeted therapies.

Engineered adenoviruses, vaccinia viruses, and reoviruses are being studied for their ability to:

• Destroy metastatic lesions
• Stimulate adaptive immunity
• Reduce tumor recurrence
• Improve treatment response in microsatellite-stable colorectal cancers

Researchers are particularly interested in combining viral therapy with immunotherapy for metastatic colorectal cancer.

 

6. Breast Cancer

Triple-Negative Breast Cancer (TNBC) remains one of the most challenging breast cancer subtypes due to its aggressive biology and limited targeted treatment options.

Oncolytic virus therapy offers promising opportunities by:

• Increasing tumor immunogenicity
• Enhancing T-cell infiltration
• Improving checkpoint inhibitor response
• Reducing metastatic spread

Clinical trials are currently evaluating HSV, vaccinia virus, and adenovirus platforms in metastatic breast cancer.

 

7. Ovarian Cancer

Ovarian cancer often recurs after initial chemotherapy, making innovative treatment strategies essential.

Oncolytic viruses are being investigated to:

• Target chemotherapy-resistant tumors
• Activate anti-tumor immunity
• Improve progression-free survival
• Enhance responses to combination immunotherapy

Intraperitoneal administration of viral therapies is also being explored to maximize local tumor control.

 

8. Prostate Cancer

Several genetically engineered adenoviruses have demonstrated encouraging activity against localized and advanced prostate cancer.

Potential benefits include:

• Selective tumor destruction
• Local immune activation
• Reduced systemic toxicity
• Combination with hormonal therapy and radiotherapy

Researchers continue to optimize viral vectors specifically designed for prostate tumor biology.

 

9. Head and Neck Cancers

Head and neck squamous cell carcinoma frequently develops immune resistance.

Clinical trials have shown that combining oncolytic viruses with immune checkpoint inhibitors may significantly improve treatment responses by increasing immune recognition of tumor cells.

Several adenovirus and HSV-based therapies remain under active investigation.

 

10. Hematologic Malignancies

Although oncolytic viruses were initially developed for solid tumors, growing evidence suggests they may also play an important role in treating blood cancers.

Researchers are studying their applications in:

• Multiple Myeloma
• Acute Myeloid Leukemia (AML)
• Lymphoma
• Chronic Lymphocytic Leukemia (CLL)

Engineered measles viruses and reoviruses have demonstrated promising anti-tumor activity in early-phase clinical studies.

 

Combination Therapy: The Future of Oncolytic Virus Treatment

One of the most exciting developments in modern oncology is the use of oncolytic viruses in combination with other advanced cancer therapies.

Current combination strategies include:

• Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4 inhibitors)
• CAR-T Cell Therapy
• Cancer Vaccines
• Targeted Therapy
• Radiotherapy
• Chemotherapy
• Personalized Neoantigen Vaccines
• Adoptive Cell Therapy

These combination approaches aim to maximize tumor destruction while generating durable, long-lasting immune protection against cancer recurrence.

Advantages of Oncolytic Virus Therapy

Oncolytic virus therapy has emerged as one of the most promising innovations in modern oncology because it offers unique therapeutic benefits that extend beyond conventional cancer treatments. Unlike chemotherapy, which often damages both cancerous and healthy rapidly dividing cells, engineered oncolytic viruses are designed to selectively target malignant cells while preserving normal tissues.

1. Selective Targeting of Cancer Cells

One of the greatest strengths of oncolytic viruses is their ability to preferentially infect tumor cells.

Cancer cells frequently exhibit:

• Defective antiviral defense mechanisms
• Altered cell signaling pathways
• Increased metabolic activity
• Abnormal receptor expression

These characteristics allow engineered viruses to replicate efficiently inside malignant cells while healthy cells successfully prevent viral replication.

This selective approach reduces unnecessary damage to normal tissues and improves treatment precision.

 

2. Dual Anti-Cancer Mechanism

Unlike many traditional therapies, oncolytic viruses attack cancer through two complementary mechanisms.

They:

• Directly destroy tumor cells through viral replication (oncolysis).
• Stimulate the patient's immune system to recognize and eliminate remaining cancer cells.

This dual action provides both immediate tumor reduction and long-term immune surveillance that may help prevent recurrence.

 

3. Enhanced Anti-Tumor Immunity

Following tumor cell destruction, numerous tumor antigens are released into the surrounding microenvironment.

These antigens activate:

• Dendritic cells
• Cytotoxic T lymphocytes
• Natural killer (NK) cells
• Helper T cells

As a result, the immune system becomes capable of identifying and attacking metastatic lesions located far from the original treatment site.

 

4. Synergy with Modern Immunotherapy

One of the most exciting advantages of oncolytic virus therapy is its ability to improve the effectiveness of existing immunotherapies.

Clinical studies have demonstrated promising results when combined with:

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4 inhibitors
• CAR-T cell therapy
• Cancer vaccines
• Targeted therapies

These combinations can convert immunologically "cold" tumors into "hot" tumors that respond more effectively to immune-based treatments.

 

5. Personalized Precision Oncology

Future treatment strategies will increasingly utilize:

• Genomic profiling
• Biomarker analysis
• Artificial intelligence
• Multi-omics integration
• Personalized molecular diagnostics

These technologies will help clinicians select the most appropriate viral platform for individual patients, maximizing treatment efficacy while minimizing toxicity.

 

Current Challenges and Limitations

Despite remarkable progress, several scientific and clinical challenges continue to limit the widespread adoption of oncolytic virus therapy.

1. Pre-Existing Antiviral Immunity

Many therapeutic viruses originate from naturally circulating viruses to which patients may already possess neutralizing antibodies.

These antibodies can:

• Eliminate therapeutic viruses before reaching tumors
• Reduce treatment effectiveness
• Limit repeated dosing

Researchers are actively developing novel viral vectors capable of evading pre-existing immunity.

 

2. Limited Delivery to Deep-Seated Tumors

Intratumoral injection provides excellent local delivery but is unsuitable for many internal cancers.

Intravenous administration remains challenging because therapeutic viruses may be rapidly cleared by:

• The liver
• The spleen
• Circulating antibodies
• The complement system

Improving systemic delivery remains a major research priority.

 

3. Tumor Microenvironment Barriers

Many cancers create an immunosuppressive tumor microenvironment that inhibits viral replication and immune activation.

Factors such as:

• Dense extracellular matrix
• Hypoxia
• Regulatory immune cells
• Immunosuppressive cytokines

may reduce treatment efficacy.

Combination therapies are being investigated to overcome these barriers.

 

4. Tumor Heterogeneity

Every tumor contains multiple genetically distinct cancer cell populations.

Some cells may be highly susceptible to viral infection, while others remain resistant.

Understanding tumor heterogeneity is essential for developing more effective personalized viral therapies.

 

5. Regulatory and Manufacturing Challenges

Developing genetically engineered viral therapeutics requires:

• Complex manufacturing facilities
• Strict biosafety regulations
• Extensive quality control
• Large-scale clinical validation

These factors increase production costs and may delay widespread clinical implementation.

 

Future Perspectives of Oncolytic Virus Therapy

The future of oncolytic virus therapy is exceptionally promising.

Researchers worldwide are exploring innovative approaches that combine virology, immunology, genomics, artificial intelligence, and precision medicine to create increasingly effective cancer treatments.

Emerging developments include:

Artificial Intelligence-Guided Viral Engineering

AI algorithms are being used to:

• Design safer viral vectors
• Predict therapeutic responses
• Identify optimal treatment combinations
• Personalize therapy based on genomic profiles

 

Next-Generation Multi-Gene Engineered Viruses

Future viruses may carry multiple therapeutic genes capable of:

• Enhancing immune activation
• Blocking tumor blood vessel formation
• Delivering cytokines
• Producing checkpoint inhibitors directly within tumors

 

Multi-Omics Integration

Combining:

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Spatial biology

will allow clinicians to select highly personalized viral therapies tailored to each patient's unique tumor biology.

 

Combination Precision Immunotherapy

Future clinical protocols are expected to combine oncolytic viruses with:

• Personalized cancer vaccines
• Bispecific antibodies
• Adoptive cell therapies
• CRISPR-based gene editing
• Neoantigen-directed immunotherapy

These integrated strategies aim to achieve deeper, longer-lasting, and potentially curative responses.

 

Expanding Clinical Applications

Current research is extending beyond melanoma into:

• Pancreatic cancer
• Glioblastoma
• Lung cancer
• Breast cancer
• Ovarian cancer
• Colorectal cancer
• Prostate cancer
• Pediatric malignancies
• Rare cancers

As clinical evidence grows, regulatory approvals are expected to expand significantly over the coming decade.

 

The Future of Precision Cancer Care

Oncolytic virus therapy represents far more than an innovative cancer treatment—it signifies a paradigm shift in oncology. By combining selective tumor destruction with powerful immune activation, engineered viruses are redefining how clinicians approach cancer therapy.

As advances in artificial intelligence, precision oncology, genomic medicine, multi-omics integration, and personalized immunotherapy continue to accelerate, oncolytic virotherapy is poised to become a cornerstone of next-generation cancer care. Future treatment strategies will increasingly focus on tailoring engineered viral therapies to each patient's unique tumor biology, ultimately improving survival, reducing toxicity, and bringing the vision of truly personalized oncology closer to reality.

Conclusion

Oncolytic Virus Therapy represents one of the most exciting breakthroughs in modern precision oncology, combining the power of virology, immunology, and genetic engineering to create highly targeted cancer treatments. Unlike conventional therapies that primarily focus on eliminating cancer cells, oncolytic viruses provide a dual therapeutic advantage by directly destroying tumor cells while simultaneously stimulating the immune system to recognize and eliminate residual disease.

The approval of Talimogene Laherparepvec (T-VEC) marked a significant milestone in the clinical application of oncolytic virotherapy, and ongoing research continues to expand its potential across multiple cancer types, including melanoma, glioblastoma, pancreatic, lung, breast, colorectal, and ovarian cancers. Advances in artificial intelligence, biomarker discovery, multi-omics integration, and personalized medicine are expected to further enhance the precision and effectiveness of engineered viral therapies.

Although challenges such as antiviral immunity, delivery strategies, tumor heterogeneity, and manufacturing complexity remain, the rapid progress in clinical research suggests that oncolytic virus therapy will play an increasingly important role in the future of cancer care. As next-generation viral platforms and combination immunotherapies continue to evolve, patients may benefit from safer, more personalized, and highly effective treatment options.

To explore the latest innovations in precision oncology, cancer immunotherapy, molecular diagnostics, artificial intelligence, biomarker research, and next-generation cancer therapeutics, join leading oncologists, researchers, clinicians, and healthcare professionals at the World Conference on Oncology & Cancer Care (WCOCC-2026), taking place November 19–21, 2026, in Tokyo, Japan.

🔗 Conference Website: https://www.oncology.theiconicmeetings.com/

WCOCC-2026 provides an international platform for scientific collaboration, knowledge exchange, and discussions on the latest breakthroughs shaping the future of oncology. Whether you are a researcher, clinician, academician, healthcare professional, or industry expert, this conference offers an excellent opportunity to share your research, build global collaborations, and contribute to advancing cancer care worldwide.

 

Frequently Asked Questions (FAQs)

1. What is Oncolytic Virus Therapy?

Oncolytic Virus Therapy is a form of cancer immunotherapy that uses genetically engineered or naturally occurring viruses to selectively infect, replicate within, and destroy cancer cells while stimulating the immune system.

2. How do oncolytic viruses kill cancer cells?

They infect cancer cells, multiply inside them, cause the cells to rupture (oncolysis), and release tumor antigens that activate immune cells to attack remaining cancer cells.

3. Is Oncolytic Virus Therapy approved for clinical use?

Yes. Talimogene Laherparepvec (T-VEC) is FDA-approved for treating certain patients with advanced melanoma, while many other viral therapies remain in clinical trials.

4. Which cancers may benefit from Oncolytic Virus Therapy?

Research is evaluating its effectiveness in melanoma, glioblastoma, pancreatic, lung, breast, colorectal, ovarian, prostate, and several other cancers.

5. Is Oncolytic Virus Therapy the same as gene therapy?

No. Although both use viral vectors, oncolytic virotherapy focuses on selectively destroying cancer cells and activating immune responses rather than replacing defective genes.

6. Can Oncolytic Virus Therapy be combined with immunotherapy?

Yes. Combining oncolytic viruses with immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and targeted therapies has shown promising results in clinical studies.

7. What are the main advantages of Oncolytic Virus Therapy?

Its major benefits include selective tumor targeting, reduced damage to healthy tissues, immune activation, and compatibility with combination therapies.

8. Are there any limitations?

Challenges include pre-existing antiviral immunity, delivery to deep tumors, tumor heterogeneity, immunosuppressive tumor microenvironments, and manufacturing complexity.

9. What role does artificial intelligence play in Oncolytic Virus Therapy?

AI helps identify therapeutic targets, predict patient responses, optimize viral engineering, and support precision treatment planning.

10. Why is Oncolytic Virus Therapy considered a future direction in oncology?

Its ability to combine precision targeting with immune activation makes it one of the most promising next-generation cancer therapies currently being investigated worldwide.

 

References

• National Cancer Institute (NCI)
• American Society of Clinical Oncology (ASCO)
• American Association for Cancer Research (AACR)
• European Society for Medical Oncology (ESMO)
• Nature Reviews Cancer
• Nature Medicine
• The New England Journal of Medicine (NEJM)
• The Lancet Oncology
• Cancer Discovery
• Clinical Cancer Research

 

Related Articles

• Artificial Intelligence in Oncology: How AI Is Transforming Cancer Care in 2026
• Cancer Neoantigen Vaccines: Revolutionizing Personalized Cancer Immunotherapy Beyond Traditional Vaccines
• CAR-T Cell Therapy: Revolutionizing Cancer Treatment Through Immunotherapy
• Bispecific Antibodies in Cancer Therapy: The Next Frontier of Precision Immuno-Oncology
• Tumor Microenvironment (TME): The Hidden Ecosystem Driving Cancer Progression and Immunotherapy Success
• Artificial Intelligence in Cancer Drug Discovery: Accelerating the Future of Precision Oncology
• Precision Oncology: The Future of Personalized Cancer Treatment
• Multi-Omics Integration in Precision Oncology: Combining Genomics, Transcriptomics, Proteomics, and Metabolomics to Transform Personalized Cancer Care